BeiGene Collaborated with DualityBio to Advance Differentiated Antibody Drug Conjugate Therapy for Solid Tumors
Shots:
- DualityBio will receive an up front and will be eligible for a contingent payment if BeiGene exercises its option, ~$1.3B in an additional fee upon achievement of development, regulatory, and commercial milestones along with royalties
- BeiGene retains global clinical, manufacturing, and commercial rights to ADC therapy upon exercising its option while DualityBio will be responsible to continue preclinical research activities and support IND filing
- The collaboration will advance both companies’ strengths to advance ADC therapies. In addition to developing 10+ novel product candidates that are currently in the preclinical stage, DualityBio has advanced four assets into global clinical studies
Ref: Businesswire | Image: BeiGene
Related News:- BeiGene’s Brukinsa (zanubrutinib) Receives the US FDA’s Approval for Chronic Lymphocytic Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
